Table 3.
Study ID | Groups = n | Age (y) | Males | BMI | Radiological Assessment | Clinical Follow-Up |
---|---|---|---|---|---|---|
Baek 202128 | Total = 58 | 65 | 59% | 25 | MRI at mean 31 ± 7 (24–37) months | mean 30.5 (24–37) months |
Intact = 27 | 66 | 52% | – | |||
Torn = 31 | 64 | 65% | – | |||
Kholinne 202018 | Total = 64 | – | 47% | – | MRI at 3, 6, 12 months and annually thereafter | mean 31.3 ± 8.2 months in mesh augment group mean 24.1 ± 4.6 months in non-mesh augment group |
Intact = 45 | 65 | – | – | |||
Torn = 19 | 63 | – | – | |||
LaBelle 202125 | Total = 21 | 63 | 68% | – | MRI at final follow-up, range 24–41 months | 24–41 months |
Intact = 8 | – | – | – | |||
Torn = 13 | – | – | – | |||
Lacheta 202029 | Total = 20 | 56 | 57% | – | MRI at mean 2.5 (0.3–10.2) months | mean 25 (24–36) months |
Intact = 10 | 56 | – | ||||
Torn = 10 | 58 | – | ||||
Lee 201830 | Total = 36 | 61 | – | 25 | US at 3 months, MRI at 6 and 12 months | 24.8 ± 6.9 months |
Intact = 23 | ||||||
Torn = 13 | ||||||
Lim 201931 | Total = 31 | 65 | 29% | – | MRI at mean 12.8 (12–24) months (intact) or mean 5.7 (3–12) months (torn) | mean 15 (12–24) months |
Intact = 22 | 64 | 44% | ||||
Torn = 9 | 67 | 27% | ||||
Shin 202232 | Total = 51 | 63 | 61% | 25 | MRI at mean 9 ± 4 (6–22) months | mean 18 ± 5.4 (12–30) months |
Intact = 36 | 64 | 58% | 26 | |||
Torn = 15 | ||||||
i = 9 | i = 65 | i = 44% | i = 23 | |||
c = 6 | c = 57 | c = 100% | c = 25 |